GlaxoSmithKline Plc rejected allegations that it concealed safety information about its diabetes drug Avandia or acted inappropriately in marketing it, saying a U.S. Senate staff report was inaccurate and incomplete.
The company diligently studied the drug’s safety and effectiveness, and communicated its findings to governments, regulators, scientists and doctors, London-based Glaxo said in a statement.
Read the full Bloomberg story here.
The U.S. Food and Drug Administration plans to convene an advisory panel hearing in July to consider the results of new studies on Avandia. Until then, patients should continue taking it, the agency said.
“The last time around, when this issue went before an advisory committee meeting, the vote was overwhelmingly in favor of leaving the drug on the market because of weakness in interpretation” of the studies. “That doesn’t mean this time around there might be a different outcome at the FDA because of the political pressure that’s being put on the agency.”
If you or a family member has been personally injured because of the fault of someone else: by the use of dangerous and defective drugs, bad products, or toxic injury etc then please contact the Dallas Texas Avandia Defective Drug Attorney Dr. Shezad Malik. For a no obligation, free case analysis, please call 214-390-3189 or Contact Me Online.
The Dr. Shezad Malik Law Firm is currently evaluating and accepting Avandia Heart Attack and Heart Failure side effect cases.